HK1119720A1 - Immunoglobulins directed against nogo - Google Patents

Immunoglobulins directed against nogo

Info

Publication number
HK1119720A1
HK1119720A1 HK08113307.3A HK08113307A HK1119720A1 HK 1119720 A1 HK1119720 A1 HK 1119720A1 HK 08113307 A HK08113307 A HK 08113307A HK 1119720 A1 HK1119720 A1 HK 1119720A1
Authority
HK
Hong Kong
Prior art keywords
directed against
immunoglobulins directed
against nogo
nogo
immunoglobulins
Prior art date
Application number
HK08113307.3A
Other languages
English (en)
Inventor
Stephanie Jane Clegg
Jonathan Henry Ellis
Volker Germaschewski
Paul Andrew Hamblin
George Kopsidas
Ruth Mcadam
Rabinder Kumar Prinjha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1119720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1119720A1 publication Critical patent/HK1119720A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
HK08113307.3A 2005-12-16 2008-12-08 Immunoglobulins directed against nogo HK1119720A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
PCT/EP2006/069737 WO2007068750A2 (fr) 2005-12-16 2006-12-14 Immunoglobulines

Publications (1)

Publication Number Publication Date
HK1119720A1 true HK1119720A1 (en) 2009-03-13

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113307.3A HK1119720A1 (en) 2005-12-16 2008-12-08 Immunoglobulins directed against nogo

Country Status (31)

Country Link
US (2) US8362208B2 (fr)
EP (2) EP1960429B1 (fr)
JP (1) JP5015949B2 (fr)
KR (1) KR101355118B1 (fr)
CN (1) CN101374863B (fr)
AR (1) AR057239A1 (fr)
AU (1) AU2006325228B2 (fr)
BR (1) BRPI0619855A2 (fr)
CA (1) CA2633501C (fr)
CR (1) CR10099A (fr)
CY (1) CY1113094T1 (fr)
DK (1) DK1960429T3 (fr)
EA (1) EA015536B1 (fr)
ES (1) ES2389380T3 (fr)
GB (1) GB0525662D0 (fr)
HK (1) HK1119720A1 (fr)
HR (1) HRP20120684T1 (fr)
IL (1) IL192086A0 (fr)
JO (1) JO2795B1 (fr)
MA (1) MA30041B1 (fr)
MY (1) MY149492A (fr)
NO (1) NO20082699L (fr)
NZ (1) NZ569143A (fr)
PE (1) PE20071099A1 (fr)
PL (1) PL1960429T3 (fr)
PT (1) PT1960429E (fr)
SI (1) SI1960429T1 (fr)
TW (1) TWI378940B (fr)
UA (1) UA96279C2 (fr)
WO (1) WO2007068750A2 (fr)
ZA (2) ZA200805111B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009258063B2 (en) 2007-06-21 2014-09-25 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
WO2009056509A1 (fr) 2007-11-02 2009-05-07 Novartis Ag Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci
UY31807A (es) 2008-05-06 2009-12-14 Glaxo Group Ltd Encapsulación de agentes biológicamente activos
WO2010004031A2 (fr) * 2008-07-11 2010-01-14 Glaxo Group Limited Traitement inédit
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
EP2870177A1 (fr) 2012-07-05 2015-05-13 Glaxo Group Limited Régime posologique optimal d'un anticorps anti-nogo-a dans le traitement de la sclérose latérale amyotrophique
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
WO2018232144A1 (fr) * 2017-06-14 2018-12-20 Monojul, Llc Anticorps anti-récepteur bêta des folates humains à affinité élevée et méthodes d'utilisation
CN114599676A (zh) 2019-10-24 2022-06-07 诺华康制药股份公司 新型抗-Nogo-A抗体
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
WO2022263864A1 (fr) 2021-06-17 2022-12-22 Petmedix Ltd Anticorps anti-cd20 canin
WO2023067358A1 (fr) 2021-10-21 2023-04-27 Petmedix Ltd Protéines comprenant le domaine extracellulaire de p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2023152486A1 (fr) 2022-02-09 2023-08-17 Petmedix Ltd Anticorps thérapeutiques
WO2024041450A1 (fr) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 Anticorps pour reconnaître de manière spécifique nogo-a et son utilisation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
EP0656064B1 (fr) 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
ATE273959T1 (de) 1994-05-27 2004-09-15 Glaxosmithkline Spa Chinolinderivate als tachykinin nk3 rezeptor antagonisten
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1997001352A1 (fr) 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions et procedes utilisant la glycoproteine associee a la myeline (mag) et ses inhibiteurs
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
DE69942803D1 (de) 1998-07-22 2010-11-11 Smithkline Beecham Ltd Rotein änhelt, und dafür kodierende cdns
MXPA01004598A (es) 1998-11-06 2002-04-24 Martin E Schwab Secuencias de nucleotidos y proteinas de los genes nogo y metodos basados en estas.
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
EP1539233B1 (fr) 2001-07-12 2011-04-27 FOOTE, Jefferson Anticorps super humanises
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
SI1711530T1 (sl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Imunoglobulini, ki nevtralizirajo NogoA, za zdravljenje nevroloških bolezni
EP1761561B1 (fr) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Transfert de specificite d'anticorps au moyen de determinants de liaison essentielle minimale
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor

Also Published As

Publication number Publication date
DK1960429T3 (da) 2012-09-24
BRPI0619855A2 (pt) 2011-10-25
SI1960429T1 (sl) 2012-09-28
UA96279C2 (ru) 2011-10-25
ES2389380T3 (es) 2012-10-25
CA2633501A1 (fr) 2007-06-21
NZ569143A (en) 2011-08-26
EA200801343A1 (ru) 2008-12-30
US20130287781A1 (en) 2013-10-31
US20100221260A1 (en) 2010-09-02
EA015536B1 (ru) 2011-08-30
IL192086A0 (en) 2008-12-29
KR101355118B1 (ko) 2014-02-06
WO2007068750A3 (fr) 2007-11-29
CR10099A (es) 2008-09-22
KR20080080644A (ko) 2008-09-04
ZA200906162B (en) 2010-05-26
AU2006325228B2 (en) 2011-12-15
MA30041B1 (fr) 2008-12-01
EP2228391A3 (fr) 2010-12-29
WO2007068750A2 (fr) 2007-06-21
EP1960429A2 (fr) 2008-08-27
CA2633501C (fr) 2015-03-31
JP2009519025A (ja) 2009-05-14
EP2228391A2 (fr) 2010-09-15
PL1960429T3 (pl) 2012-11-30
HRP20120684T1 (hr) 2012-09-30
AU2006325228A1 (en) 2007-06-21
US8362208B2 (en) 2013-01-29
NO20082699L (no) 2008-09-08
EP1960429B1 (fr) 2012-06-27
CN101374863A (zh) 2009-02-25
TW200801038A (en) 2008-01-01
TWI378940B (en) 2012-12-11
MY149492A (en) 2013-09-13
JP5015949B2 (ja) 2012-09-05
GB0525662D0 (en) 2006-01-25
ZA200805111B (en) 2009-12-30
AR057239A1 (es) 2007-11-21
PE20071099A1 (es) 2007-11-22
JO2795B1 (en) 2014-03-15
PT1960429E (pt) 2012-09-25
CY1113094T1 (el) 2016-04-13
CN101374863B (zh) 2013-05-29

Similar Documents

Publication Publication Date Title
HK1119720A1 (en) Immunoglobulins directed against nogo
WO2005061544A3 (fr) Immunoglobulines
WO2006058868A8 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
ATE526987T1 (de) Dr5-antikörper und deren verwendung
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2007047112A3 (fr) Anticorps anti-myostatine
HK1116073A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
TW200709817A (en) Platform antibody compositions
ES2391382T8 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
HK1116803A1 (en) Novel anti-plgf antibody
MX2010003574A (es) Anticuerpos il-23.
WO2007002884A3 (fr) 4-fluoro-piperidines antagonistes du canal calcium de type t
WO2007002361A3 (fr) Antagonistes du canal calcique de type t 3-fluoro-piperidine
SI1900362T1 (sl) Derivati alfa-aminoamida, uporabni pri zdravljenju odvisnosti
TW200628473A (en) Novel heterocycles
HK1136874A1 (en) Modulators of neuronal regeneration
TW200740808A (en) Inhibiteurs de proteines kinases
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
PL1838716T3 (pl) Dihydrat embonianu olanzapiny
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151214